Special Autumn 2025CDMOs & CROsThe Trump administration’s trade policy has hit CDMOs and CROs hard. Trade barriers against Chinese service providers and raw material suppliers have increased biologics production costs and caused … more ➔
Special Summer 2025Lab automation: New ModalitiesMore visitors, more exhibitors and more new product launches at SLAS Europe in Hamburg. more ➔
Special Summer 2025Euro BioFairs CompassGuide to Life Sciences Events in the second half year of 2025 more ➔
Special Summer 2025(Bio)EngineeringRegions and industry leaders are already preparing for the future. This Special spotlights emerging open innovation clusters and cutting-edge bioengineering platforms. more ➔
Special Spring 2025Oligonucleotides and PeptidesPeptide drugs recorded global sales in Europe. The market for gene and cell therapy contract manufacturing, oligonucleotide synthesis and the production of viral vectors and plasmids is also expanding … more ➔
Special Winter 2025Preview: Drug Delivery ServicesAlthough smart drug delivery accounts for only 10% of drug development costs, significant efforts have been made to optimise drug properties such as solubility, stability and release kinetics, while … more ➔
Special Winter 2025Preview: Talent scouting & educationFaced with a severe shortage of skilled labour, specialised biopharma companies and service providers such as CROs and CDMOs are competing globally for the best minds. Active recruitment and retention … more ➔
Special Winter 2025Preview: Automation in quality controlBy modelling the (bio)manufacturing processes digitally, companies can simulate different conditions, optimise parameters, and improve efficiency without disrupting actual production. Using a simulation … more ➔
Special Winter 2024Protein Engineering and ServicesMonoclonal antibodies still dominate the US$417bn biologics market. After decades of development, however, improved antibodies and protein formats with better target selectivity and safety profiles … more ➔
Special Autumn 2024CDMOs & CROsA draft US Biosecure Act being passed by the US House of Representatives and discussed by the US Senate could prohibit US biotech developers from collaborating with Chinese CROs, CDMOs and drug developers … more ➔
